A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2013

At a glance

  • Drugs Denosumab (Primary)
  • Indications Bone resorption; Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jan 2011 New source identified and integrated (ClinicalTrials.gov).
    • 21 Jan 2011 Lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top